- Home
- REFI vs DCTH Comparison
REFI vs DCTH Comparison
Compare REFI & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- DCTH
- Stock Information
- Founded
- REFI 2021
- DCTH 1988
- Country
- REFI United States
- DCTH United States
- Employees
- REFI N/A
- DCTH 76
- Industry
- REFI Real Estate Investment Trusts
- DCTH Medical/Dental Instruments
- Sector
- REFI Real Estate
- DCTH Health Care
- Exchange
- REFI Nasdaq
- DCTH Nasdaq
- Market Cap
- REFI 304.4M
- DCTH 485.5M
- IPO Year
- REFI 2021
- DCTH N/A
- Fundamental
- Price
- REFI $14.23
- DCTH $12.51
- Analyst Decision
- REFI Strong Buy
- DCTH Strong Buy
- Analyst Count
- REFI 3
- DCTH 4
- Target Price
- REFI $20.00
- DCTH $24.00
- AVG Volume (30 Days)
- REFI 104.8K
- DCTH 772.3K
- Earning Date
- REFI 08-06-2025
- DCTH 08-04-2025
- Dividend Yield
- REFI 13.17%
- DCTH N/A
- EPS Growth
- REFI N/A
- DCTH N/A
- EPS
- REFI 1.88
- DCTH N/A
- Revenue
- REFI $56,790,054.00
- DCTH $53,850,000.00
- Revenue This Year
- REFI $15.53
- DCTH $155.42
- Revenue Next Year
- REFI $6.70
- DCTH $37.93
- P/E Ratio
- REFI $7.59
- DCTH N/A
- Revenue Growth
- REFI 4.68
- DCTH 1068.87
- 52 Week Low
- REFI $12.76
- DCTH $7.17
- 52 Week High
- REFI $16.47
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- REFI 48.08
- DCTH 31.52
- Support Level
- REFI $13.85
- DCTH $13.30
- Resistance Level
- REFI $14.59
- DCTH $14.15
- Average True Range (ATR)
- REFI 0.28
- DCTH 0.65
- MACD
- REFI 0.00
- DCTH -0.28
- Stochastic Oscillator
- REFI 49.15
- DCTH 0.29
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.